Cordis To Enroll 400 Patients In SIRIUS Trial After Conditional IDE

Johnson & Johnson's Cordis unit announced plans to begin enrolling 400 of the 1,100 patients selected for its Rapamune-eluting coronary stent clinical trial in the U.S. immediately following conditional investigational device exemption approval by FDA on Feb. 5.